Department of Dermatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, P. R. China.
Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, P. R. China.
J Cell Biochem. 2018 Jan;119(1):640-649. doi: 10.1002/jcb.26225. Epub 2017 Jul 31.
For the treatment of stage III/IV malignant melanoma (MM), a network meta-analysis (NMA) was conducted to compare the short and long-term efficacy of targeted therapy with single or double-drug regimens. All conducted randomized controlled trials (RCTs) searched from PubMed and Cochrane Library were included in the study for direct and indirect comparison for MM. The odds ratio (OR) and surface under the cumulative ranking curves (SUCRA) value of the targeted therapy with single or double-drug regimens for treatment of stage III/IV MM were also analyzed. To group the treatments according to their similarity with regards to both outcomes, cluster analyses were performed. Ultimately, 16 RCTs were incorporated for this NMA. The NMA revealed that the overall response rate (ORR) values of single-drug regimens (Vemurafenib [Vem], Dabrafenib [Dab], and Nivolumab [Niv]) were higher than those of Dacarbazine (Dac). Also the ORR values of double-drug regimens (Dab + Trametinib [Dab + Tra], Niv + Ipilimumab [Niv + Ipi], and Vem + Cobimetinib [Vem + Cob]) were moderately higher than those of Dac. The results of the SUCRA showed that short-term efficacy of single-drug regimens (Vem and Dab) were better, while the short-term efficacy of double-drug regimens (Dab + Tra and Vem + Cob) were relatively better. It was determined that Vem, Dab, and Niv might be the best choice in evaluating the treatment of stage III/IV MM among different single-drug targeted therapy regimens, while Dab + Tra, Niv + Ipi, and Vem + Cob might have better short-term efficacy among different double-drug targeted therapy regimens. J. Cell. Biochem. 119: 640-649, 2018. © 2017 Wiley Periodicals, Inc.
为了治疗 III/IV 期恶性黑色素瘤（MM），进行了一项网络荟萃分析（NMA），以比较靶向治疗单药和双药方案的短期和长期疗效。所有从 PubMed 和 Cochrane Library 中检索到的已发表的随机对照试验（RCT）都被纳入了本研究，用于对 MM 进行直接和间接比较。还分析了靶向治疗单药和双药方案治疗 III/IV 期 MM 的疗效的比值比（OR）和累积排序曲线下面积（SUCRA）值。为了根据两种结果对治疗方法进行分组，进行了聚类分析。最终，这项 NMA 纳入了 16 项 RCT。NMA 结果显示，单药方案（vemurafenib [Vem]、dabrafenib [Dab] 和 nivolumab [Niv]）的总体缓解率（ORR）值高于达卡巴嗪（Dac）。双药方案（Dab+ trametinib [Dab+Tra]、Niv+ ipilimumab [Niv+Ipi] 和 Vem+ cobimetinib [Vem+Cob]）的 ORR 值也略高于 Dac。SUCRA 的结果表明，单药方案（Vem 和 Dab）的短期疗效较好，而双药方案（Dab+Tra 和 Vem+Cob）的短期疗效相对较好。在不同的单药靶向治疗方案中，vemurafenib（Vem）、dabrafenib（Dab）和 nivolumab（Niv）可能是评估 III/IV 期 MM 治疗的最佳选择，而在不同的双药靶向治疗方案中，Dab+Tra、Niv+Ipi 和 Vem+Cob 可能具有更好的短期疗效。J. Cell. Biochem. 119: 640-649, 2018. © 2017 Wiley Periodicals, Inc.
